ILC Therapeutics completes £2.5m financing and bolsters C-suite

ILC Therapeutics, a specialist developer of hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications, announces that it has successfully completed a fundraise of £2.5m.

Read More »